• Acetylcysteine for ROS and Pyroptosis Assays

  2026-09-30

  Acetylcysteine provides a practical redox-perturbation tool for testing whether photodynamic therapy damage depends on ROS rather than nonspecific toxicity. This workflow translates a breast cancer pyroptosis study into reproducible assay controls, concentration screens, and troubleshooting decisions.

• Triacetin for Metabolic–Epigenetic Assay Design

  2026-09-30

  Triacetin is more than a short-chain triglyceride: its hydrolysis, metabolic signaling, and context-dependent cytotoxicity can shape assay interpretation. This guide combines Triacetin biology with lessons from an epigenetic immuno-oncology study to develop better controls, readouts, and translational boundaries.

• Topotecan HCl Workflows for DNA Damage Studies

  2026-09-29

  Topotecan HCl provides a controllable topoisomerase 1 inhibitor workflow for linking replication-associated DNA damage with cytotoxicity, apoptosis, and treatment resistance. This guide combines cancer-model applications with a carefully bounded neuroinflammation connection inspired by recent CUX2 neuron-loss research.

• 3X (DYKDDDDK) Peptide: Workflow Guide

  2026-09-29

  The 3X (DYKDDDDK) Peptide combines a compact, hydrophilic epitope with three recognition repeats for sensitive capture, elution, and detection of recombinant proteins. This guide connects routine FLAG workflows with structural biology, metal-sensitive assays, and the Nsp1–NXF1/NXT1 host-pathogen mechanism.

• MK 0893: From Receptor Mechanism to Translation

  2026-09-28

  MK 0893 is a competitive, reversible glucagon receptor antagonist that connects allosteric receptor biology with cAMP pharmacology, animal-model validation, and translational strategy for type 2 diabetes research.

• Bivalent mRNA–LNP Vaccine Protects Chickens from H5/H7

  2026-09-28

  Wei and colleagues evaluated a nucleoside-modified mRNA–LNP vaccine encoding H5N1 and H7N9 hemagglutinins in SPF chickens. The study reports dose-dependent antibody responses, protection at the tested high doses against several homologous and heterologous challenges, and reduced viral replication and shedding—promising results that still require validation beyond the SPF model.

• Nifedipine and PXR: Separating Assay Questions

  2026-09-27

  Nifedipine (BAY-a-1040) is an L-type calcium-channel tool, not a PXR probe. This article explains how to keep calcium signaling experiments distinct from evidence on PXR-driven liver regeneration and CYP activity—and how that distinction improves assay interpretation.

• Meropenem Research Workflows for Resistance Studies

  2026-09-26

  Build a reproducible Meropenem workflow that connects susceptibility phenotypes with resistance-genotype and infection-model questions. Practical assay starting points, formulation cautions, and clear limits help distinguish broad-spectrum activity from activity against carbapenem-resistant isolates.

• Marein Inhibits ABCG2 to Restore Chemosensitivity

  2026-09-25

  A 2024 study reports that marein, a flavonoid from Coreopsis tinctoria, competitively inhibits ABCG2 and increases the intracellular accumulation of transporter-substrate chemotherapy drugs. Cell-based findings support further investigation of marein as a chemosensitizing research lead, while leaving its clinical relevance and safety unresolved.

• Erastin Workflows for Ferroptosis Research

  2026-09-25

  Use Erastin to probe cystine–glutathione stress and ferroptotic vulnerability in tumor-cell models, then strengthen interpretation with lipid-oxidation and iron-linked readouts. This practical workflow also shows how to adapt the assay to nasopharyngeal carcinoma radioresistance research without assuming that every ferroptosis result proves radiosensitization.

• ML216 BLM Helicase Inhibitor: Assay Workflow

  2026-09-24

  Use ML216 to test BLM-dependent DNA repair with a workflow that pairs biochemical helicase measurements with matched cellular controls. Practical guidance also distinguishes BLM-focused experiments from the separate WRN vulnerability reported in mismatch-repair-deficient colorectal cancer.

• HFM1 Variant Disrupts Zygotic Genome Activation

  2026-09-24

  A case-based study links a homozygous HFM1 variant to abnormal RNA splicing, loss of nuclear localization, and failure of zygotic genome activation (ZGA) in arrested human embryos. Mouse knockdown and rescue experiments support a functional role for HFM1 in early development, while the single-case design means prevalence and broader clinical significance remain uncertain.

• Coelenterazine Workflows for ROS and Reporter Assays

  2026-09-23

  Coelenterazine supports both reactive-oxygen-species readouts and compatible luciferase reporter workflows, but those signals need distinct controls and interpretations. This practical guide links substrate handling and assay optimization to lessons from a brain–kidney AVP study without implying that the study itself used Coelenterazine.

• Imipramine: Autophagy, Apoptosis & Assay Design

  2026-09-23

  Imipramine is a tricyclic antidepressant used in research on serotonin transport, autophagy, apoptosis, neuroprotection, and immune signaling. Product information reports an approximately 32 nM serotonin-transporter binding IC50, while cancer-cell findings support controlled glioma and leukemia assay development rather than clinical conclusions.

• Phalloidin B7678: F-Actin Workflow Guide

  2026-09-22

  Phalloidin (SKU B7678) is a high-affinity F-actin probe for preserving and assessing filament organization in fixed, permeabilized cells, tissue sections, and cell-free assays. It is intended for endpoint cytoskeleton visualization, not live-cell imaging or experiments that require reversible actin turnover.

8054 records 1/537 page Next 12345 下5页 Last page